Journal scan

‘No evidence’ for use of drug to curb excess drinking

At a time when the NHS is strapped for cash, money should not be spent on a drug supposed to deter people from drinking, claim editors.
Excess drinking

At a time when the NHS is strapped for cash, money should not be spent on a drug supposed to deter people from drinking, claim editors.

There is ‘no direct evidence’ to support the effectiveness of nalmefene, the drug approved for use in the NHS in England by the National Institute for Health and Care Excellence (NICE) to curb excess drinking among those who are alcohol dependent.

That’s the conclusion of editors of the BMJ’s Drug and Therapeutics Bulletin, who argue that evidence of clinical or cost effectiveness of the drug is weak.

Incongruous

'At a time when the NHS is removing some basic items from prescription, it seems incongruous that it continues to fund nalmefene despite having no real understanding of its actual impact on patient outcomes,’ they

...

Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Nursing Standard
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?

Jobs